ABBV Jan 2023 115.000 call
| Previous close | 12.40 |
| Open | 11.55 |
| Bid | 10.85 |
| Ask | 12.00 |
| Strike | 115.00 |
| Expiry date | 2023-01-20 |
| Day's range | 10.75 - 11.55 |
| Contract range | N/A |
| Volume | 66 |
| Open interest | 2.93k |
- Zacks
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
- PR Newswire
AbbVie to Present at the Evercore ISI Conference
AbbVie (NYSE: ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 11:10 a.m. CT.
- PR Newswire
AbbVie to Present at the Piper Sandler Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 9:30 a.m. CT.
